Advertisement
UK markets closed

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • CRUDE OIL

    85.35
    -0.06 (-0.07%)
     

  • GOLD FUTURES

    2,407.00
    +24.00 (+1.01%)
     

  • DOW

    37,890.02
    +154.91 (+0.41%)
     

  • Bitcoin GBP

    49,897.98
    -1,589.41 (-3.09%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,885.16
    +0.14 (+0.00%)
     

  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Quanta to Present at the LifeSci Partners Private Company Summer Symposium

Quanta Dialysis Technologies
·2-min read

ALCESTER, England and BEVERLY, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, today announced that John E. Milad, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on July 21-23, 2021. Please click this link to register for the event.

Presentation Details:

Date:

July 22, 2021

Time:

10:30am Eastern Time

About Quanta Dialysis and SC+
Quanta is enabling the future of kidney care, with a mission to bring to market solutions that improve the delivery of dialysis and help people live more freely. Headquartered in the UK and with operations in the US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.

ADVERTISEMENT

Quanta’s lead product, SC+, is a small and simple, powerful hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home.

The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

Learn more at Quantadt.com.

For more information about Quanta, please contact:

Quanta
Kavita Bouknight
E: press@Quantadt.com

Investors
Jeremy Feffer
E: jeremy@lifesciadvisors.com